Ingevity Stock Forecast, Price & News

Ingevity (NYSE:NGVT) Frequently Asked Questions

Is Ingevity a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ingevity stock.
View analyst ratings for Ingevity or view top-rated stocks.

How has Ingevity's stock price been impacted by Coronavirus?

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NGVT shares have increased by 96.8% and is now trading at $76.36.
View which stocks have been most impacted by COVID-19.

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Ingevity.

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) posted its earnings results on Wednesday, October, 27th. The company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.08. The business had revenue of $376.80 million for the quarter, compared to analysts' expectations of $354.29 million. Ingevity had a trailing twelve-month return on equity of 35.46% and a net margin of 10.11%. The firm's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.79 EPS.
View Ingevity's earnings history.

What guidance has Ingevity issued on next quarter's earnings?

Ingevity issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.32 billion-$1.36 billion, compared to the consensus revenue estimate of $1.35 billion.

What price target have analysts set for NGVT?

4 Wall Street analysts have issued 1-year price objectives for Ingevity's stock. Their forecasts range from $81.00 to $112.00. On average, they expect Ingevity's share price to reach $93.00 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price.
View analysts' price targets for Ingevity or view top-rated stocks among Wall Street analysts.

Who are Ingevity's key executives?

Ingevity's management team includes the following people:

• John C. Fortson, President, CEO, Treasurer & Director
• Marty Heyne, Senior Vice President-Operations
• Mary Dean Hall, Chief Financial Officer & Executive Vice President
• Mike Smith, EVP, President-Strategy & Business Development
• Stacy Lancaster Cozad, Secretary, Vice President & General Counsel

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity CEO John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among Ingevity's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Ingevity's key competitors?

Some companies that are related to Ingevity include Olin (OLN), Huntsman (HUN), Ashland Global (ASH), Johnson Matthey (JMPLY), Balchem (BCPC), Chemours (CC), Univar Solutions (UNVR), Livent (LTHM), Showa Denko K.K. (SHWDY), Kuraray (KURRY), GCP Applied Technologies (GCP), Innospec (IOSP), SL Industries (SLI), Ecovyst (ECVT) and Hawkins (HWKN).
View all of NGVT's competitors.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.82%), Boston Partners (5.20%), Wellington Management Group LLP (2.96%), LSV Asset Management (2.77%), Broad Bay Capital Management LP (2.39%) and Ardevora Asset Management LLP (1.95%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends for Ingevity.

Which major investors are selling Ingevity stock?

NGVT stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, BlackRock Inc., Primecap Management Co. CA, Broad Bay Capital Management LP, Two Sigma Advisers LP, Two Sigma Investments LP, Royal Bank of Canada, and Invesco Ltd..
View insider buying and selling activity for Ingevity or view top insider-selling stocks.

Which major investors are buying Ingevity stock?

NGVT stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Millennium Management LLC, Ararat Capital Management LP, Renaissance Technologies LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, BNP Paribas Asset Management Holding S.A., and Putnam Investments LLC. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson.
View insider buying and selling activity for Ingevity or or view top insider-buying stocks.

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $76.36.

How much money does Ingevity make?

Ingevity has a market capitalization of $3.00 billion and generates $1.22 billion in revenue each year. The company earns $181.40 million in net income (profit) each year or $3.42 on an earnings per share basis.

How many employees does Ingevity have?

Ingevity employs 1,750 workers across the globe.

What is Ingevity's official website?

The official website for Ingevity is www.ingevity.com.

Where are Ingevity's headquarters?

Ingevity is headquartered at 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406.

How can I contact Ingevity?

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The company can be reached via phone at (844) 643-8489, via email at [email protected], or via fax at 843-740-8165.